Ally Bridge Group (ny) LLC 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Ally Bridge Group (ny) LLC disclosed 21 US equity positions worth $100.7m in its Q1 2026 13F filing. The largest position was PRAX at 10.5% of the reported book, followed by NERV and SLNOEUR.
What did Ally Bridge Group (ny) LLC own in Q1 2026? Top 21 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 10.5% | $10.6m | 32,810 | – | |
| 2 | NERV MINERVA NEUROSCIENCES INC | 9.9% | $10.0m | 1,655,500 | – | ||
| 3 | SLNOEUR SOLENO THERAPEUTICS INC | 6.7% | $6.7m | 200,000 | – | ||
| 4 | OVID OVID THERAPEUTICS INC | Healthcare | 6.2% | $6.3m | 2,818,459 | – | |
| 5 | CMPS COMPASS PATHWAYS PLC | Healthcare | 5.7% | $5.8m | 1,045,000 | – | |
| 6 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 5.6% | $5.7m | 80,859 | – | |
| 7 | SLDB SOLID BIOSCIENCES INC | Healthcare | 5.5% | $5.5m | 766,974 | – | |
| 8 | PROMIS NEUROSCIENCES INC | 5.2% | $5.3m | 414,219 | – | ||
| 9 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 5.0% | $5.1m | 161,000 | – | |
| 10 | EPRX EUPRAXIA PHARMACEUTICALS INC | 4.7% | $4.8m | 660,375 | – | ||
| 11 | CTMX CYTOMX THERAPEUTICS INC. | Healthcare | 4.2% | $4.2m | 900,000 | – | |
| 12 | IVA INVENTIVA SA | 4.1% | $4.1m | 745,300 | – | ||
| 13 | CATX PERSPECTIVE THERAPEUTICS INC | 3.8% | $3.9m | 926,557 | – | ||
| 14 | ABVX ABIVAX SA | Healthcare | 3.7% | $3.8m | 33,712 | – | |
| 15 | ALMS ALUMIS INC | Healthcare | 3.7% | $3.7m | 166,959 | – | |
| 16 | URGN UROGEN PHARMA LTD | Healthcare | 3.6% | $3.6m | 202,124 | – | |
| 17 | CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 3.4% | $3.5m | 113,899 | – | |
| 18 | WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 2.8% | $2.8m | 817,939 | – | |
| 19 | IKT INHIBIKASE THERAPEUTICS INC | 2.2% | $2.2m | 1,325,000 | – | ||
| 20 | ANTX AN2 THERAPEUTICS INC | 1.8% | $1.8m | 526,315 | – | ||
| 21 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.5% | $1.5m | 210,525 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.